by uimmodulon_admin | 29th April 2024 | Press Releases
Uxbridge, United Kingdom – April 29, 2024 – Immodulon, a late-stage clinical biotechnology company focused on developing a broad spectrum immunomodulator to improve the lives of patients suffering from difficult-to-treat cancers, today announced that Gertjan Bartlema,...
by John Bachtiger | 12th December 2023 | Press Releases
Professor Dr. med. Thomas Seufferlein appointed Chair of new Scientific Advisory Board (SAB) composed of leaders with deep expertise in the clinical oncology field New SAB to complement significant oncology drug development experience of Immodulon’s new management...
by uimmodulon_admin | 26th June 2023 | Press Releases
Richard Couch, formerly at Celgene, appointed as Chief Technology Officer Owen Vaughan, formerly at Taiho Oncology, appointed as Chief Regulatory Officer Appointments add decades of industry experience to support advancement of IMM-101 into a pivotal trial in...
by Sandi Greenwood | 5th June 2023 | Press Releases
Josefine Roemmler-Zehrer, former Medical Director at Ipsen & Celgene, brings broad global clinical and medical affairs expertise Adding further oncology experience to Immodulon’s leadership team as the company prepares to advance IMM-101 into a pivotal trial in...
by Sandi Greenwood | 10th May 2023 | Press Releases
Richard Davies, Deputy Chairman of Alvotech, elected as Chairman of the Board Gertjan Bartlema, formerly at Celgene and Amgen, appointed as Chief Executive Officer Peter Greaney, formerly at ADC Therapeutics and Celgene, appointed as Chief Business Officer...
by uimmodulon_admin | 14th June 2022 | Press Releases
Seasoned global biopharmaceutical executives add significant clinical and commercial experience to Immodulon Dr. Selwyn Ho and Gertjan Bartlema will join the Board with immediate effect Uxbridge, UK – 14 June 2022 – Immodulon Therapeutics Limited, the immuno-oncology...
by Sandi Greenwood | 7th June 2022 | Publication
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer | British Journal of Cancer (nature.com) Dalgleish, A., Stebbing, J., Adamson, D. et al. Randomised, open-label, phase II study of gemcitabine with and...
by uimmodulon_admin | 7th June 2022 | Press Releases
IMM-101 in combination with nivolumab was well-tolerated and demonstrated encouraging efficacy data Primary endpoints were met, including 73% Overall Response Rate (ORR) in treatment-naïve patients with advanced melanoma Uxbridge, UK, 7 June 2022 – Immodulon...
by uimmodulon_admin | 25th March 2021 | archive
First patient enrolled in a phase I/II study for IMM-101 in limited metastatic pancreatic cancer patients at Erasmus University Medical Center Erasmus MC initiates recruitment for new investigator-sponsored phase I/II study to investigate the safety and efficacy of...
by uimmodulon_admin | 15th March 2021 | archive
Presentation on circulatory immunological biomarkers in cancer patients and novel technologies during clinical trials Uxbridge, UK – 15 March 2021 – Immodulon, the immuno-oncology company, announces that its Chief Scientific Officer, Dr. Thomas Kleen, will present at...